rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ELOX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Eloxx Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
      Nov 16Yahoo FinanceELOX
      Eloxx Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for Exaluren in Nonsense-Mutation ADPKD
      Oct 29MorningstarELOX
      Eloxx Pharmaceuticals adds Geno Germano to board of directors
      Oct 19Investing.comELOX
      Eloxx Pharmaceuticals Appoints Biopharmaceutical Industry Veteran Geno Germano to its Board of Directors
      Oct 19Yahoo FinanceELOX
      This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thur

      Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.

      Oct 15BenzingaELOX
      Eloxx Pharmaceuticals Announces First Patients Dosed in Phase 2b EXACT Study of Exaluren in Nonsense Mutation Alport Syndrome

      Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the first two patients have been dosed in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome (NMAS).

      Sep 11Yahoo FinanceELOX
      Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL)

      Tipranks Press Release.

      Aug 25The Globe and MailCINGELOXAGL

      This is the newest page. Registered accounts read further back.